Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

166

Enrollment

NETWORK

Sponsor class

Conditions

ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Interventions

OTHER: Clinical Observation
DRUG: Crizotinib
OTHER: Laboratory Biomarker Analysis

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]